Hibah Awwad, Ph.D.

Clinical Assistant Professor

Department of Pharmaceutical Sciences

Phone (405) 271-6593 x47210

Fax (405) 271-7505

Office CPB 315

Email hawwad@ouhsc.edu


Traumatic brain injury (TBI) is a leading cause of death and disability in young adults. To date, there are no FDA-approved drugs for TBI. The main focus of our research is to study the mechanisms of neurotoxic factors released after a brain injury, in order to identify potential targets for novel neuroprotective therapies. Scientific methods include neuropharmacology via molecular, biochemical, behavioral and imaging techniques.

Education & Experience

Ph.D. in Pharmacology

University of Houston, Houston, TX


B.Sc. in Pharmacy

Amman University, Amman, Jordan


Certificate in Preparing Future Faculty

University of Oklahoma Health Sciences Center, Oklahoma City, OK


Honors & Awards

Professional Awards

Provost's Teaching Award for Early Career Faculty

University of Oklahoma Health Sciences Center, OKC, OK

Educator of the Year Award

University of Oklahoma College of Pharmacy

AACP WalMart Scholar

American Association of Colleges of Pharmacy (San Antonio general meeting)

Academic Awards

Postdoctoral Travel Award

Society for Neuroscience (Washington, DC)


Postdoctoral Research Award (for scientific achievement - travel award)

Graduate College; University of Oklahoma Health Sciences Center, OKC, OK


Postdoctoral Scientific Research Award - Neuropharmacology Division

ASPET. Experimental Biology/Federation of American Societies. Experimental Biology (Anaheim, CA)


John B. Bruce Scholarship Award - Outstanding postdoctoral fellow in pharmaceutical Sciences

OU College of Pharmacy, Oklahoma City, OK


Publications & Presentations

1 2 3 4 > >>
    1. Awasthi V, Awwad H O, Houson H, Hedrick A, Mdzinarishvili A, Standifer K. Hemorrhagic Shock Aggravates Traumatic Brain Injury: Evidence from PET Imaging Using 18F-Fluorodeoxyglucaric Acid in a Rat Model. BRAIN INJURY. 2019; 33 : 117-118

    2. Baier M P, Lerner M R, Awwad H O. Histamine Release in Traumatic Brain Injury: Neurotoxic or Neuroprotective. American Journal of Pharmaceutical Education. 2018; 82 : 555

    3. Awwad H O, Durand C D, Gonzalez L P, Tompkins P, Zhang Y, Lerner M R, Brackett D J, Sherry D M, Awasthi V, Standifer K. Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions. Behavioural brain research. 2018

    4. Baier M, Lerner M R, Awwad H O. Temporal changes in mast cell release following a mild traumatic brain injury in rats. Society for Neuroscience Annual Meeting Proceedings. 2017

    5. Oleru A V, Edwards A C, Awwad H O. Mild traumatic brain injury increases histamine-3-receptor expression. Journal of Neurotrauma. 2017; 34 : A-103

1 2 3 4 > >>


    1. Pharmacotherapy of Traumatic Brain Injury Accompanied by Hemorrhagic Shock NIH. Start Date: 2017. End Date: 2021.

    2. Temporal changes in cerebrospinal histamine correlate with neurobehavioral deficits following mild traumatic brain injury in rats NSF. Start Date: 2019. End Date: 2019.

    3. Histamine release in Traumatic Brain Injury: neurotoxic or neuroprotective? AACP. Start Date: 2017. End Date: 2017.

    4. Unveiling neurotoxic mechanisms in a traumatic brain injury model Misc Non-Federal. Start Date: 2015. End Date: 2016.

    5. Molecular mechanisms of chronic pain and its modulation by posttraumatic stress disorder and Nociceptin/Orphanin FQ DOD. Start Date: 2011. End Date: 2015.